📊 KOD Key Takeaways
Is Kodiak Sciences Inc. (KOD) a Good Investment?
Kodiak Sciences is a pre-revenue biopharmaceutical company burning $40M+ annually in operating cash flow with no current revenue generation. While the balance sheet is strengthened by $169.5M in cash and zero debt, providing approximately 4 years of runway at current burn rates, the company exhibits significant cash destruction (-51.9% ROE, -19.0% ROA) with worsening diluted EPS trends. Fundamental profitability is entirely dependent on achieving successful regulatory approval and market commercialization.
Kodiak Sciences is pre-revenue with deep operating losses that worsened YoY, producing severely negative ROE/ROA and heavy cash burn. Liquidity is solid near term (strong current ratio, ~$210M cash, no debt), but the ~$136M annual FCF burn implies a limited runway and likely future dilution. Without visibility into sustainable revenue or materially reduced operating expenses, fundamentals remain unfavorable.
Kodiak Sciences Inc. Key Strengths (KOD)
- Strong cash position of $169.5M provides meaningful runway for development and operations
- Zero long-term debt and zero Debt/Equity ratio provides financial flexibility and eliminates refinancing risk
- Excellent liquidity ratios (3.54x current and quick ratios) ensure ability to fund near-term obligations
- Strong liquidity with 4.72x current/quick ratio and ~$210M cash
- Zero leverage (no long-term debt)
- Minimal capex needs, preserving financial flexibility
KOD Stock Risks: Kodiak Sciences Inc. Investment Risks
- No meaningful revenue generation; company is pre-commercial and entirely dependent on pipeline success
- Significant operating losses of $59.8M and negative free cash flow of $41M indicate unsustainable burn rate requiring external capital or revenue realization
- Negative ROE and ROA show shareholder value destruction; EPS deteriorating at 29% YoY despite cash reserves
- Approximately 4-year cash runway at current burn rate; company must achieve clinical/regulatory milestones or secure additional financing
- Persistent, widening net losses and negative operating income
- High cash burn reduces runway and raises dilution risk
- No revenue visibility; dependence on external financing or milestones
Key Metrics to Watch
- Time to revenue generation and regulatory approval milestones for lead candidates
- Quarterly operating cash flow burn rate relative to cash runway
- Changes in total cash position and cash burn trajectory relative to program advancement
- Operating cash flow (quarterly burn rate)
- Cash & equivalents and months of runway
Kodiak Sciences Inc. (KOD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.54x current ratio provides a solid financial cushion.
KOD Profit Margin, ROE & Profitability Analysis
KOD vs Healthcare Sector: How Kodiak Sciences Inc. Compares
How Kodiak Sciences Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Kodiak Sciences Inc. Stock Overvalued? KOD Valuation Analysis 2026
Based on fundamental analysis, Kodiak Sciences Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Kodiak Sciences Inc. Balance Sheet: KOD Debt, Cash & Liquidity
KOD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Kodiak Sciences Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.97 indicates the company is currently unprofitable.
KOD Revenue Growth, EPS Growth & YoY Performance
Kodiak Sciences Inc. Dividends, Buybacks & Capital Allocation
KOD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Kodiak Sciences Inc. (CIK: 0001468748)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KOD
What is the AI rating for KOD?
Kodiak Sciences Inc. (KOD) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KOD's key strengths?
Claude: Strong cash position of $169.5M provides meaningful runway for development and operations. Zero long-term debt and zero Debt/Equity ratio provides financial flexibility and eliminates refinancing risk. ChatGPT: Strong liquidity with 4.72x current/quick ratio and ~$210M cash. Zero leverage (no long-term debt).
What are the risks of investing in KOD?
Claude: No meaningful revenue generation; company is pre-commercial and entirely dependent on pipeline success. Significant operating losses of $59.8M and negative free cash flow of $41M indicate unsustainable burn rate requiring external capital or revenue realization. ChatGPT: Persistent, widening net losses and negative operating income. High cash burn reduces runway and raises dilution risk.
What is KOD's revenue and growth?
Kodiak Sciences Inc. reported revenue of N/A.
Does KOD pay dividends?
Kodiak Sciences Inc. does not currently pay dividends.
Where can I find KOD SEC filings?
Official SEC filings for Kodiak Sciences Inc. (CIK: 0001468748) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KOD's EPS?
Kodiak Sciences Inc. has a diluted EPS of $-0.94.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is KOD's fundamental grade?
Based on our AI fundamental analysis in May 2026, Kodiak Sciences Inc. has a C grade with 74% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is KOD stock overvalued or undervalued?
Valuation metrics for KOD: ROE of -51.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is KOD's AI grade for 2026?
Our dual AI analysis gives Kodiak Sciences Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KOD's free cash flow?
Kodiak Sciences Inc.'s operating cash flow is $-40.0M, with capital expenditures of $942.0K.
How does KOD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -51.9% (avg: 15%), current ratio 3.54 (avg: 2).